https://cambridgebrc.nihr.ac.uk/wp-content/uploads/2024/09/Cambridge_Biomedical_Research_Centre_Cytosponge1-1024x683-1.jpg
683
1024
Amanda
https://cambridgebrc.nihr.ac.uk/wp-content/uploads/2024/04/Cambridge_BRC_NIHR_logo.png
Amanda2024-11-28 11:06:032025-01-10 18:10:43Landmark ‘Pill-On-A-Thread’ cancer screening trial welcomes first participantsThe NIHR Cambridge BRC is part of the NIHR and hosted by Cambridge University Hospitals NHS Foundation Trust in partnership with the University of Cambridge. We are at the heart of the Cambridge Biomedical Campus, Europe’s largest health research area.
Contact Us
Cambridge Biomedical Research Centre
Box 277
Hills Road
Cambridge
CB2 0QQ
Tel: 01223 348490
⏲️One week left to apply for our Researcher Development Programme for Social Care Nurses!
This programme supports social care nurses to develop research skills and explore ideas arising from their day-to-day practice, while remaining in role.
Apply now: https://www.nihr.ac.uk/career-development/researcher-development-programme-social-care-nurses?utm_source=twitter&utm_medium=social&utm_campaign=rdp2026
📢 Interested in Programme Grants for Applied Research (PGfAR) - October 2026?
There’s still time to join our webinar and find out more about this upcoming funding opportunity.
💻 29 June 2026 | 2.30–4pm
In partnership with @RCPCHtweets, this funding will support ambitious,
📣 Come and spend a day with the Cambridge NeuroWorks team showcasing the latest developments in #neurotech on Monday 15 June!
🔎 Learn about this exciting area of #research & #innovation with @CPFT_NHS to improve healthcare & treatments.
⚡Register ASAP ➡️https://cambridgeneuroworks.org/news-events/neuroworks-2026-scalable-neurotechnology-innovation-translation-and-transformative-treatments
We're expanding research, widening treatment options and tackling inequalities in prostate cancer care.
✅ All eligible Black men will be invited to join a landmark screening trial.
✅ A targeted NHS screening programme will also be rolled out.
More: https://www.gov.uk/government/news/major-expansion-of-research-and-treatment-for-prostate-cancer


















RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial